VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
The expansion of the patent portfolio is a significant milestone for VERAXA as it seeks to establish a strong competitive position in the rapidly evolving field of cancer immunotherapy. By securing intellectual property protection for its BiTAC platforms and related technologies, the company aims to create barriers to entry for competitors and ensure that its innovations remain exclusive for years to come. This is particularly important given the growing interest in bispecific antibodies and antibody-drug conjugates as promising approaches for treating various cancers.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's pipeline includes bispecific T cell engagers and bispecific ADCs, which are designed to harness the body's immune system to target and destroy cancer cells more effectively than traditional therapies.
The implications of this announcement are far-reaching for the oncology industry and patients. With over 50 patents now in its portfolio, VERAXA is positioning itself as a leader in next-generation cancer therapy development. The protected technologies could lead to more targeted and safer treatments, potentially improving outcomes for patients with hard-to-treat cancers. For investors, the strong IP position may enhance the company's valuation and attractiveness as a partner or acquisition target.
For those interested in the full details of the press release, additional information is available at https://ibn.fm/BqhFS. The latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
